Skip to main content

and
  1. No Access

    Article

    Salvage lymphadenectomy in recurrent prostate cancer: is there evidence of real benefit?

    Nodal recurrent prostate cancer (PCa) after primary radical treatment represents a heterogeneous entity with many treatment options. In some cases, surgical removal of metastatic nodes seems to improve cancer ...

    F. Pisano, J. M. Gaya, A. Breda, J. Palou in World Journal of Urology (2019)

  2. No Access

    Article

    Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

    The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not...

    J. Palou, F. Pisano, R. Sylvester, S. Joniau, V. Serretta in World Journal of Urology (2018)

  3. No Access

    Chapter

    Adjuvant Treatment: Old and New Immunotherapy in Non-Muscle-Invasive Bladder Cancer

    Bacillus Calmette-Guérin (BCG) is the first connection between bladder cancer and immunotherapy and still represents the gold standard treatment for intermediate and high-risk non-muscle-invasive bladder cance...

    J. Palou, F. Pisano in Treating Urothelial Bladder Cancer (2018)